← Back to Search

Other

Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans

Phase 1
Waitlist Available
Research Sponsored by Azevan Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 7 days

Summary

This trial tests SRX246, a drug aimed at reducing fear and anxiety, on people who feel anxious or scared. It measures how the drug affects their startle response and emotion recognition.

Eligible Conditions
  • Botox

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 7 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in startle reflex between SRX246 and Placebo
Secondary study objectives
Change in State Anxiety Scale between SRX246 and Placebo
Change in emotional expression recognition between SRX246 and Placebo

Side effects data

From 2016 Phase 1 & 2 trial • 97 Patients • NCT02055638
6%
Dry Mouth
6%
Diarrhea
6%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
SRX246
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SRX246Experimental Treatment1 Intervention
SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
Group II: PlaceboPlacebo Group1 Intervention
Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SRX246
2009
Completed Phase 2
~280

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Azevan PharmaceuticalsLead Sponsor
7 Previous Clinical Trials
436 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,928 Previous Clinical Trials
2,744,983 Total Patients Enrolled
~4 spots leftby Dec 2025